Lifeline Biotechnologies Supports Susan G. Komen Foundation Annual Walk for the Cure
RENO, Nev., Oct. 27, 2011 /PRNewswire/ — Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) announced today that its First Warning Systems, in keeping with Breast Cancer Month, is supporting a Reno-based women’s team participating in the annual Susan G. Komen 3-Day Walk for the Cure in San Diego, CA, November 18 – 20th.
This team is comprised of a number of concerned activists including two breast cancer survivors. First Warning Systems is sponsoring in full two members of the team: a 46 year old breast cancer survivor and single mother of three whose cancer was missed by the mammogram. She also sits on one of the Komen Chapter Boards. Another team member is a 40 year old two-time cancer survivor who was diagnosed with breast cancer at the age of 28. These women are avid supporters of the First Warning System (FWS) early detection device, an accurate, non-invasive screening test validated with over 500 women in three rounds of clinical trials.
The FWS has been developed to address and solve the poor performance rates of existing breast cancer screening modalities. The FWS, unlike the mammographic screening process, is non-invasive and does not involve compression or radiation. The test involves placing a discrete sensor array under the bra which records skin surface temperatures over a specific period of time. The recorded data reflects the change of deep tissue temperatures over time, potentially representing various stages of angiogenesis, an indicator of cancer. The captured data is transmitted to the FWS interpretive center where the data is processed by a proprietary network of algorithms trained to identify various forms and stages of breast tissue abnormalities, then returned to the physician’s office to enhance and assist in the physicians’ clinical recommendations.
In its development and clinical trials, the FWS has attained sensitivity (false positive) and specificity (false negative) of over 90%, compared to mammographic screening which ranges in 70% accuracy rates. It is well known that the mammogram is missing or misdiagnosing approximately 30% of the cancers it screens for. The FWS was developed to increase the safe and effective level of early detection accuracy at the screening level, enabling a superior treatment regime, as well as to reduce the need for unnecessary procedures often recommended due to uncertain and vague mammographic screening results, especially in young women and women with dense breast tissue. First Warning Systems is preparing for a final round clinical trial expected to be limited in the number of patients required according to and in compliance with FDA guidelines. Following this limited clinical trial a medical device submission is to be filed with the FDA for marketing clearance.
Updating, DTC has not removed the “Chill” on Lifeline’s stock. The Company’s efforts continue to get the “Chill” removed, although the success and timing remain uncertain.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company’s product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.
CONTACT: Lifeline Biotechnologies, Inc. Jim Holmes, 775-326-9614 Email: Jholmes@lbti.com website: www.lbti.com
SOURCE Lifeline Biotechnologies, Inc.